In SLE, adding dapirolizumab pegol vs. placebo to usual care improved disease activity at 48 wk.
- DOI
- 10.7326/annals-26-03185-jc
- Published
- 2026 Sep
- Container
- Annals of internal medicine
- Publisher
- Not recorded
- Open access
- unknown
Credibility signals
limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.7326/annals-26-03185-jc,
title = {In SLE, adding dapirolizumab pegol vs. placebo to usual care improved disease activity at 48 wk.},
author = {Lafita FR and Schattner A and ACP Journal Club Editorial Team at McMaster University},
year = {2026},
journal = {Annals of internal medicine},
doi = {10.7326/annals-26-03185-jc},
url = {https://doi.org/10.7326/annals-26-03185-jc}
}RIS
TY - JOUR TI - In SLE, adding dapirolizumab pegol vs. placebo to usual care improved disease activity at 48 wk. AU - Lafita FR AU - Schattner A AU - ACP Journal Club Editorial Team at McMaster University PY - 2026 JO - Annals of internal medicine DO - 10.7326/annals-26-03185-jc UR - https://doi.org/10.7326/annals-26-03185-jc ER -
APA
FR, L., A, S., & University, A. J. C. E. T. A. M. (2026). In SLE, adding dapirolizumab pegol vs. placebo to usual care improved disease activity at 48 wk.. Annals of internal medicine. https://doi.org/10.7326/annals-26-03185-jc
Source records
- pubmed · retrieved 2026-09-25T21:27:33.920Z